A5046176016- Advanced Radiotherapy Techniques
- Breast Cancer Treatment Studies
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Head and Neck Cancer Studies
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Diagnosis and Treatment
- Advances in Oncology and Radiotherapy
- Brain Metastases and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Medical Imaging Techniques and Applications
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Glioma Diagnosis and Treatment
- Breast Implant and Reconstruction
- Lung Cancer Research Studies
- Management of metastatic bone disease
- Effects of Radiation Exposure
- Radiation Dose and Imaging
- Radiation Therapy and Dosimetry
Azienda Ospedaliero-Universitaria Careggi
2016-2025
University of Florence
2016-2025
Humanitas University
2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
Ospedale SS. Annunziata
2020
Ghent University Hospital
2019
Presidio Ospedaliero
2017-2019
Azienda Socio Sanitaria Territoriale Lariana
2019
University of Trieste
2017-2019
Ospedale San Giuseppe
2017-2019
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, clinically meaningful overall (OS) effect PD-L1-positive aTNBC. The KEYNOTE-355 trial adding pembrolizumab to chemotherapy aTNBC similar PFS effects. IMpassion131...
To report the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) Florence phase III trial comparing whole-breast (WBI) to APBI in early-stage breast cancer.The primary end point was determine 5-year difference ipsilateral tumor recurrence (IBTR) between 30 Gy 5 once-daily fractions (APBI arm) and 50 25 with a bed boost (WBI after breast-conserving surgery.Five hundred twenty patients, more than 90% whom had...
To evaluate the effect of plan parameters on volumetric modulated arc therapy (VMAT) dosimetric accuracy, together with possibility scoring complexity.142 clinical VMAT plans initially optimized using a 4° control point (CP) separation were evaluated. All delivered by 6 MV Linac to biplanar diode array for patient-specific quality assurance (QA). Local Γ index analysis (3%, 3 mm and 2%, 2 mm) enabled comparison between calculated dose. The following considered each plan: average leaf travel...
PURPOSE ARTO (ClinicalTrials.gov identifier: NCT03449719 ) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in patients with oligometastatic castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS All were affected by CRPC as defined three or less nonvisceral metastatic lesions. Patients randomly assigned 1:1 receive either AAP alone (control arm) concomitant SBRT...
The present study investigated the efficacy and safety of nivolumab in pre-treated patients with advanced NSCLC harbouring KRAS mutations.Clinical data mutational status were analysed treated within Italian Expanded Access Program. Objective response rate, progression-free survival overall evaluated. Patients monitored for adverse events using National Cancer Institute Common Terminology Criteria Adverse Events.Among 530 evaluated mutations, 206 (39%) positive while 324 (61%) wild-type...
Objectives. The authors reported a retrospective study on myxoid liposarcomas (MLs), evaluating factors that may influence overall survival (OS), local recurrence-free (LRFS), metastasis-free (MFS), and analyzing the metastatic pattern. Methods. 148 MLs were analyzed. sites of metastases investigated. Results. Margins (<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:math> = 0.002), grading...
Abstract Background HER2-targeting agents have dramatically changed the therapeutic landscape of HER2+ advanced breast cancer (ABC). Within a short time frame, rapid introduction new therapeutics has led to approval pertuzumab combined with trastuzumab and taxane in first-line, emtansine (T-DM1) second-line. Thereby, evidence T-DM1 efficacy following trastuzumab/pertuzumab combination is limited, data from some retrospective reports suggesting lower activity. The purpose present study...